Chemotherapy dosing in achondroplastic dwarfism: a case report and review of literature.

Abstract

WHAT IS KNOWN AND OBJECTIVE:

CASE DESCRIPTION: A 74-year-old female with achondroplastic dwarfism was diagnosed with ER-, BR- and HER2- breast cancer. No guideline currently exists to direct chemotherapy dosing in this population. She received neoadjuvant chemotherapy based on body surface area utilizing actual height and weight with dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with the use of granulocyte colony-stimulating factor. Satisfactory clinical response and remission were achieved, and treatment proceeded without any significant toxicity or delays.

WHAT IS NEW AND CONCLUSION:

In the absence of guideline recommendations, dosing chemotherapy based on actual height and weight in patients with achondroplastic dwarfism may be safe and appropriate.

• Authors: R Elsoueidi, C Gresham, L Michael, D Chaney, H Mourad
• Journal: Journal of clinical pharmacy and therapeutics (J Clin Pharm Ther) Vol. 41 Issue 6 Pg. 733-735 (Dec 2016) ISSN: 1365-2710 [Electronic] England
• PMID: 27709641 (Publication Type: Case Reports)
• Copyright: © 2016 John Wiley & Sons Ltd.

Chemical References

• Doxorubicin
• Cyclophosphamide
• Paclitaxel

Topics

• Achondroplasia (pathology)
• Aged
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
• Breast Neoplasms (drug therapy, pathology)
• Cyclophosphamide (administration & dosage)
• Doxorubicin (administration & dosage)
• Drug Administration Schedule
• Female
• Humans
• Neoadjuvant Therapy (methods)
• Paclitaxel (administration & dosage)